Compound, Composition, and Method for Treating Cancer

The invention is a novel compound for treating cancer, Demethylpenclomedine, which is a derivative of the drug Penclomedine. Penclomedine is already under investigation for its remarkable preclinical activity against breast cancer, but it suffers from several dose-limiting side effects. The invention, Demethylpenclomedine, appears to have reduced toxicity while still having a similar therapeutic efficacy to that of Penclomedine in animal models. Demethylpenclomedine may thus prove to be a useful chemotherapeutic against breast cancer and other cancers. The lower toxicity may allow use at higher levels than have been tried with Penclomedine, and other possible cancers, such as brain tumors, could be targeted.

Inventors:
Neil Hartman

Intellectual Property:
U.S. Patent  No. 6,235,761 issued 2001-05-22
US Application No. PCT/US97/09428

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-013-1996/0
Updated: Jul 1, 1998